Core Scientific Inc. (CORZ)
Core Scientific Statistics
Share Statistics
Core Scientific has 294.89M shares outstanding. The number of shares has increased by 65.44% in one year.
| Shares Outstanding | 294.89M |
| Shares Change (YoY) | 65.44% |
| Shares Change (QoQ) | 5.32% |
| Owned by Institutions (%) | 92.75% |
| Shares Floating | 256.65M |
| Failed to Deliver (FTD) Shares | 595.41K |
| FTD / Avg. Volume | 3.42% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.73 and the forward PE ratio is 19.35. Core Scientific's PEG ratio is 0.
| PE Ratio | -2.73 |
| Forward PE | 19.35 |
| PS Ratio | 7.04 |
| Forward PS | 0.6 |
| PB Ratio | -4.38 |
| P/FCF Ratio | -69.04 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Core Scientific.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.72, with a Debt / Equity ratio of -1.46.
| Current Ratio | 6.72 |
| Quick Ratio | 6.72 |
| Debt / Equity | -1.46 |
| Debt / EBITDA | -1.04 |
| Debt / FCF | -23.04 |
| Interest Coverage | -0.52 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.57M |
| Profits Per Employee | $-4.05M |
| Employee Count | 325 |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 859K |
| Effective Tax Rate | -0.07% |
Stock Price Statistics
The stock price has increased by 95.11% in the last 52 weeks. The beta is 6.83, so Core Scientific's price volatility has been higher than the market average.
| Beta | 6.83 |
| 52-Week Price Change | 95.11% |
| 50-Day Moving Average | 9.03 |
| 200-Day Moving Average | 11.85 |
| Relative Strength Index (RSI) | 37.01 |
| Average Volume (20 Days) | 17.42M |
Income Statement
In the last 12 months, Core Scientific had revenue of 510.67M and earned -1.32B in profits. Earnings per share was -5.14.
| Revenue | 510.67M |
| Gross Profit | 121.07M |
| Operating Income | -19.2M |
| Net Income | -1.32B |
| EBITDA | -1.16B |
| EBIT | -1.28B |
| Earnings Per Share (EPS) | -5.14 |
Balance Sheet
The company has 836.2M in cash and 1.2B in debt, giving a net cash position of -363.57M.
| Cash & Cash Equivalents | 836.2M |
| Total Debt | 1.2B |
| Net Cash | -363.57M |
| Retained Earnings | -3.74B |
| Total Assets | 1.6B |
| Working Capital | 769.4M |
Cash Flow
In the last 12 months, operating cash flow was 42.9M and capital expenditures -94.96M, giving a free cash flow of -52.06M.
| Operating Cash Flow | 42.9M |
| Capital Expenditures | -94.96M |
| Free Cash Flow | -52.06M |
| FCF Per Share | -0.2 |
Margins
Gross margin is 23.71%, with operating and profit margins of -3.76% and -257.5%.
| Gross Margin | 23.71% |
| Operating Margin | -3.76% |
| Pretax Margin | -257.34% |
| Profit Margin | -257.5% |
| EBITDA Margin | -226.56% |
| EBIT Margin | -3.76% |
| FCF Margin | -10.2% |
Dividends & Yields
CORZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CORZ is $18, which is 182.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $18 |
| Price Target Difference | 182.1% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
Scores
| Altman Z-Score | -4.52 |
| Piotroski F-Score | 4 |